Tag: kidney function

Sobi and Apellis: Aspaveli®/Empaveli® Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases

STOCKHOLM, June 6, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase...

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

WALTHAM, Mass. and STOCKHOLM, June 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi^® (STO:SOBI) today presented new data from the open-label period of the Phase 3 VALIANT study, investigating EMPAVELI^® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The data were presented as part of a late-breaking session at the European Renal Association (ERA) Congress.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsKidney function

Finnate Listed on PathFin.ai Knowledge Hub under the MAS Pathfinder Programme Following Independent Review and Verification Process

SK Telecom and NVIDIA Build AI Infrastructure to Power Korea’s AI Innovation

VolitionRx Announces Pricing of $4.6 Million Public Offering

Tag: kidney function

Sobi and Apellis: Aspaveli®/Empaveli® Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us